- Home
- FULC vs PRTC Comparison
FULC vs PRTC Comparison
Compare FULC & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FULC
- PRTC
- Stock Information
- Founded
- FULC 2015
- PRTC 2015
- Country
- FULC United States
- PRTC United States
- Employees
- FULC N/A
- PRTC N/A
- Industry
- FULC Biotechnology: Pharmaceutical Preparations
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- FULC Health Care
- PRTC Health Care
- Exchange
- FULC Nasdaq
- PRTC Nasdaq
- Market Cap
- FULC 469.0M
- PRTC 428.7M
- IPO Year
- FULC 2019
- PRTC N/A
- Fundamental
- Price
- FULC $7.87
- PRTC $17.00
- Analyst Decision
- FULC Buy
- PRTC
- Analyst Count
- FULC 7
- PRTC 0
- Target Price
- FULC $10.43
- PRTC N/A
- AVG Volume (30 Days)
- FULC 618.0K
- PRTC 1.6K
- Earning Date
- FULC 10-29-2025
- PRTC 08-28-2025
- Dividend Yield
- FULC N/A
- PRTC N/A
- EPS Growth
- FULC N/A
- PRTC N/A
- EPS
- FULC N/A
- PRTC 0.20
- Revenue
- FULC N/A
- PRTC $6,391,000.00
- Revenue This Year
- FULC N/A
- PRTC N/A
- Revenue Next Year
- FULC N/A
- PRTC N/A
- P/E Ratio
- FULC N/A
- PRTC $7.90
- Revenue Growth
- FULC 2752.05
- PRTC 1265.60
- 52 Week Low
- FULC $2.32
- PRTC $13.30
- 52 Week High
- FULC $10.11
- PRTC $24.99
- Technical
- Relative Strength Index (RSI)
- FULC 40.58
- PRTC 45.61
- Support Level
- FULC $8.42
- PRTC $17.00
- Resistance Level
- FULC $9.47
- PRTC $17.85
- Average True Range (ATR)
- FULC 0.80
- PRTC 0.17
- MACD
- FULC -0.21
- PRTC -0.10
- Stochastic Oscillator
- FULC 7.11
- PRTC 15.03
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.